Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ostex waits on Nasdaq delisting hearing:

This article was originally published in Clinica

Executive Summary

Seattle, Washington-based Ostex is to appear before a Nasdaq listing qualifications panel in the hope that it may overturn its March 18 delisting decision until its planned merger with Inverness Medical Innovations (see Clinica No 1047, p 17) is closed or terminated is expected. This to occur during the second quarter of 2003. Nasdaq's decision to delist the company, a developer and commercialiser of disease management products, was based on it failing to satisfy the minimum $10m stockholders equity requirement. If the review is unsuccessful, Ostex will have to seek a listing on the OTC bulletin board or similar.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel